Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33883138.
- Also identified by DOI 10.1126/sciadv.abf4865 and PMC identifier 8059921.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP) are key regulators of metabolism. Here, we report a previously unknown function for the hepatic FXR-SHP axis in controlling protein N-linked glycosylation. Transcriptome analysis in liver-specific Fxr-Shp double knockout (LDKO) livers revealed induction of genes encoding enzymes in the N-glycosylation pathway, including <i>Mgat5</i>, <i>Fut8</i>, <i>St3gal6</i>, and <i>St6gal1</i> FXR activation suppressed <i>Mgat5</i>, while Shp deletion induced <i>St3gal6</i> and <i>St6gal1</i> Increased percentages of core-fucosylated and triantennary glycan moieties were seen in LDKO livers, and proteins with the "hyperglycoforms" preferentially localized to exosomes and lysosomes. This up-regulation of N-glycosylation machinery was specific to the Golgi apparatus and not the endoplasmic reticulum. The increased glycan complexity in the LDKO correlated well with dilated unstacked Golgi ribbons and alterations in the secretion of albumin, cholesterol, and triglycerides. Our findings demonstrate a role for the FXR-SHP axis in maintaining glycoprotein diversity in the liver.
Medical subject headings
- Liver
- Receptors, Cytoplasmic and Nuclear